Business
Novartis’ canakinumab failed to improve survival in Phase III trial
Published by linker 5
Posted on March 9, 2021
Related Articles
The Stability Premium: Why Businesses That Master Uncertainty Will Define the Next Decade
The Quiet Reinvention of Business: Why the Most Successful Companies Are Learning to Think Slower in a Faster World
The Quiet Advantage: Why the Most Resilient Businesses Are Winning Without Making Noise
The Productivity Illusion: Why Businesses Are Busier Than Ever but Growing Slower
The Human Advantage: Why Businesses Are Rediscovering the Value of People in the Age of Artificial Intelligence
More from Business
Explore more articles in the Business category
The Invisible Edge: Why the Companies That Adapt Quietly Are Outperforming Everyone Else
The Great Workplace Reset: Why Businesses Are Rethinking Everything They Once Knew About Productivity
The Decision Crisis Inside Modern Business: Why Companies Have More Data Than Ever but Less Clarity
The Companies That Will Survive the Future May Not Be the Ones Anyone Expects
The Real Cost of Expanding to the US: Hidden Costs Founders and Startups Must Know
The Business Implications of the New PCI Security Framework
Javier Loya on Why an Ownership Mindset Is Critical to Building Enduring Businesses
The Value Shift: Why Intangible Assets Now Define Business Worth
The Trust Economy: Why Reputation Is Becoming the Ultimate Currency
The Speed Illusion: Why Faster Decisions Don’t Always Win
The Resilience Premium: Why Stability Is Becoming More Valuable Than Growth
The Profit Paradox: Why Growth No Longer Guarantees Value